Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy

Adam Carrico, Steven Shoptaw, Christopher Cox, Ronald Stall, Xiuhong Li, David G. Ostrow, David Vlahov, Michael W. Plankey

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: HIV-positive persons who use stimulants (eg, methamphetamine) experience profound health disparities, but it remains unclear whether these persist after highly active antiretroviral therapy (HAART) initiation. Conducted within the Multicenter AIDS Cohort Study, this investigation examined whether stimulant use is associated with progression to AIDS or all-cause mortality after the initiation of HAART. Methods: Using marginal structural modeling, the cumulative proportion of visits where any stimulant use was reported (ie, 0%, 1%-49%, 50%-99%, and 100%) was examined as a time-varying predictor of (1) all-cause mortality and (2) AIDS or all-cause mortality. Results: Among the 1313 men who have sex with men (MSM) who initiated HAART, findings showed no significant association of any level of stimulant use with all-cause mortality. A competing risk analysis indicated that no level of stimulant use was associated with increased AIDS-related or non-AIDS mortality separately. Among the 648 participants without AIDS at HAART initiation, a secondary analysis indicated that stimulant use at 50% or more of study visits was associated with a 1.5-fold increase in the odds of progression to AIDS or all-cause mortality (adjusted odds ratio = 1.54; 95% confidence interval: 1.02 to 2.33; P < 0.05). Conclusions: HIV-positive stimulant-using MSM receiving HAART seem to face no greater overall risks for all-cause, AIDS-related, or non-AIDS mortality compared with nonusers. However, men without AIDS at HAART initiation who more frequently reported stimulant use demonstrated modestly increased odds of progression to AIDS or all-cause mortality. Comprehensive approaches are needed to optimize the effectiveness of HAART with stimulant-using MSM.

Original languageEnglish (US)
Pages (from-to)508-513
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume67
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Mortality
HIV
Methamphetamine
Cohort Studies
Odds Ratio
Confidence Intervals
Health

Keywords

  • Cocaine
  • Highly active antiretroviral therapy
  • HIV/AIDS
  • Methamphetamine
  • Mortality

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy. / Carrico, Adam; Shoptaw, Steven; Cox, Christopher; Stall, Ronald; Li, Xiuhong; Ostrow, David G.; Vlahov, David; Plankey, Michael W.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 67, No. 5, 01.01.2014, p. 508-513.

Research output: Contribution to journalArticle

Carrico, Adam ; Shoptaw, Steven ; Cox, Christopher ; Stall, Ronald ; Li, Xiuhong ; Ostrow, David G. ; Vlahov, David ; Plankey, Michael W. / Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy. In: Journal of Acquired Immune Deficiency Syndromes. 2014 ; Vol. 67, No. 5. pp. 508-513.
@article{f7a45dc0c73e42bf9ab82b5b56dd67e4,
title = "Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy",
abstract = "Background: HIV-positive persons who use stimulants (eg, methamphetamine) experience profound health disparities, but it remains unclear whether these persist after highly active antiretroviral therapy (HAART) initiation. Conducted within the Multicenter AIDS Cohort Study, this investigation examined whether stimulant use is associated with progression to AIDS or all-cause mortality after the initiation of HAART. Methods: Using marginal structural modeling, the cumulative proportion of visits where any stimulant use was reported (ie, 0{\%}, 1{\%}-49{\%}, 50{\%}-99{\%}, and 100{\%}) was examined as a time-varying predictor of (1) all-cause mortality and (2) AIDS or all-cause mortality. Results: Among the 1313 men who have sex with men (MSM) who initiated HAART, findings showed no significant association of any level of stimulant use with all-cause mortality. A competing risk analysis indicated that no level of stimulant use was associated with increased AIDS-related or non-AIDS mortality separately. Among the 648 participants without AIDS at HAART initiation, a secondary analysis indicated that stimulant use at 50{\%} or more of study visits was associated with a 1.5-fold increase in the odds of progression to AIDS or all-cause mortality (adjusted odds ratio = 1.54; 95{\%} confidence interval: 1.02 to 2.33; P < 0.05). Conclusions: HIV-positive stimulant-using MSM receiving HAART seem to face no greater overall risks for all-cause, AIDS-related, or non-AIDS mortality compared with nonusers. However, men without AIDS at HAART initiation who more frequently reported stimulant use demonstrated modestly increased odds of progression to AIDS or all-cause mortality. Comprehensive approaches are needed to optimize the effectiveness of HAART with stimulant-using MSM.",
keywords = "Cocaine, Highly active antiretroviral therapy, HIV/AIDS, Methamphetamine, Mortality",
author = "Adam Carrico and Steven Shoptaw and Christopher Cox and Ronald Stall and Xiuhong Li and Ostrow, {David G.} and David Vlahov and Plankey, {Michael W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/QAI.0000000000000364",
language = "English (US)",
volume = "67",
pages = "508--513",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "5",

}

TY - JOUR

T1 - Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy

AU - Carrico, Adam

AU - Shoptaw, Steven

AU - Cox, Christopher

AU - Stall, Ronald

AU - Li, Xiuhong

AU - Ostrow, David G.

AU - Vlahov, David

AU - Plankey, Michael W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: HIV-positive persons who use stimulants (eg, methamphetamine) experience profound health disparities, but it remains unclear whether these persist after highly active antiretroviral therapy (HAART) initiation. Conducted within the Multicenter AIDS Cohort Study, this investigation examined whether stimulant use is associated with progression to AIDS or all-cause mortality after the initiation of HAART. Methods: Using marginal structural modeling, the cumulative proportion of visits where any stimulant use was reported (ie, 0%, 1%-49%, 50%-99%, and 100%) was examined as a time-varying predictor of (1) all-cause mortality and (2) AIDS or all-cause mortality. Results: Among the 1313 men who have sex with men (MSM) who initiated HAART, findings showed no significant association of any level of stimulant use with all-cause mortality. A competing risk analysis indicated that no level of stimulant use was associated with increased AIDS-related or non-AIDS mortality separately. Among the 648 participants without AIDS at HAART initiation, a secondary analysis indicated that stimulant use at 50% or more of study visits was associated with a 1.5-fold increase in the odds of progression to AIDS or all-cause mortality (adjusted odds ratio = 1.54; 95% confidence interval: 1.02 to 2.33; P < 0.05). Conclusions: HIV-positive stimulant-using MSM receiving HAART seem to face no greater overall risks for all-cause, AIDS-related, or non-AIDS mortality compared with nonusers. However, men without AIDS at HAART initiation who more frequently reported stimulant use demonstrated modestly increased odds of progression to AIDS or all-cause mortality. Comprehensive approaches are needed to optimize the effectiveness of HAART with stimulant-using MSM.

AB - Background: HIV-positive persons who use stimulants (eg, methamphetamine) experience profound health disparities, but it remains unclear whether these persist after highly active antiretroviral therapy (HAART) initiation. Conducted within the Multicenter AIDS Cohort Study, this investigation examined whether stimulant use is associated with progression to AIDS or all-cause mortality after the initiation of HAART. Methods: Using marginal structural modeling, the cumulative proportion of visits where any stimulant use was reported (ie, 0%, 1%-49%, 50%-99%, and 100%) was examined as a time-varying predictor of (1) all-cause mortality and (2) AIDS or all-cause mortality. Results: Among the 1313 men who have sex with men (MSM) who initiated HAART, findings showed no significant association of any level of stimulant use with all-cause mortality. A competing risk analysis indicated that no level of stimulant use was associated with increased AIDS-related or non-AIDS mortality separately. Among the 648 participants without AIDS at HAART initiation, a secondary analysis indicated that stimulant use at 50% or more of study visits was associated with a 1.5-fold increase in the odds of progression to AIDS or all-cause mortality (adjusted odds ratio = 1.54; 95% confidence interval: 1.02 to 2.33; P < 0.05). Conclusions: HIV-positive stimulant-using MSM receiving HAART seem to face no greater overall risks for all-cause, AIDS-related, or non-AIDS mortality compared with nonusers. However, men without AIDS at HAART initiation who more frequently reported stimulant use demonstrated modestly increased odds of progression to AIDS or all-cause mortality. Comprehensive approaches are needed to optimize the effectiveness of HAART with stimulant-using MSM.

KW - Cocaine

KW - Highly active antiretroviral therapy

KW - HIV/AIDS

KW - Methamphetamine

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=84927619052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927619052&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000364

DO - 10.1097/QAI.0000000000000364

M3 - Article

C2 - 25271387

AN - SCOPUS:84927619052

VL - 67

SP - 508

EP - 513

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 5

ER -